0.4450CADMkt Cap: 30.23M CADP/E: —Last update: 2026-05-21
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which i…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap30.23M CAD
Enterprise Value32.41M CAD
Revenue (TTM)158.08K CAD
Gross Profit-450.37K CAD
Net Income (TTM)-1.55M CAD
Revenue/Share0.0020 CAD
Last Price0.4450 CAD
Fiscal Year EndSep 2025
MR QuarterDec 2025
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue205.05
P/S191.24
P/B-8.24
EPS (TTM)-0.04
EPS (Forward)—
52W Range
0.4250100% of range0.4450
52W High0.4450 CAD
52W Low0.4250 CAD
Profitability
Gross Margin-284.90%
Oper. Margin-1481.29%
EBITDA Margin0.00%
Profit Margin0.00%
ROE40.00%
ROA-1485.45%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.53M CAD
CapEx (TTM)—
FCF Margin-481.62%
FCF Yield-2.52%
Net Debt2.63M CAD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.64
Current Ratio0.01
Quick Ratio0.00
Book Value/Sh-0.0540 CAD
Cash/Share0.0000 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateSep 13, 2000
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.67.93M
Float52.33M
Insiders19.17%
Institutions0.00%
Short Interest
Short Ratio0.3d
Short % Out.0.03%
Shares Short27.11K
Short (prev mo.)16.90K
Technical
SMA 500.5194 (-14.3%)
SMA 2001.053 (-57.7%)
Beta2.05
S&P 52W Chg28.31%
Avg Vol (30d)29.00K
Avg Vol (10d)74.80K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—